Forian Inc. (NASDAQ:FORA) Short Interest Update

Forian Inc. (NASDAQ:FORAGet Free Report) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 132,400 shares, a decline of 11.3% from the November 15th total of 149,200 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 17,100 shares, the days-to-cover ratio is currently 7.7 days.

Forian Stock Up 2.0 %

Forian stock traded up $0.04 during midday trading on Tuesday, hitting $2.04. The company’s stock had a trading volume of 18,522 shares, compared to its average volume of 16,417. The stock’s 50-day moving average price is $2.07 and its 200-day moving average price is $2.33. The company has a market capitalization of $63.27 million, a PE ratio of -22.67 and a beta of 1.07. Forian has a 12 month low of $1.97 and a 12 month high of $4.15.

Analyst Upgrades and Downgrades

Separately, Roth Mkm reaffirmed a “buy” rating and issued a $5.00 price target on shares of Forian in a research note on Thursday, November 14th.

View Our Latest Research Report on Forian

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Canton Hathaway LLC increased its stake in Forian by 2.3% in the 3rd quarter. Canton Hathaway LLC now owns 269,650 shares of the company’s stock worth $582,000 after purchasing an additional 6,125 shares in the last quarter. Caprock Group LLC purchased a new stake in Forian in the 2nd quarter worth about $230,000. Finally, Elser Financial Planning Inc acquired a new stake in Forian during the 2nd quarter worth about $1,885,000. Institutional investors and hedge funds own 19.25% of the company’s stock.

About Forian

(Get Free Report)

Forian Inc provides a suite of data management capabilities, and information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in the healthcare and related industries. It develops commercial, real world evidence (RWE), and market access solutions and proprietary data-driven insights, as well as offers data management solutions.

Read More

Receive News & Ratings for Forian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forian and related companies with MarketBeat.com's FREE daily email newsletter.